full-length SARS-CoV-2 – Communicable Diseases Research

NVX-CoV2373 vaccination induces functional SARS-CoV-2-specific CD4+ and CD8+ T cell responses

Article

Published on 2022-10-032022-11-15
Journal: The Journal of Clinical Investigation
[Category] COVID19(2023년), SARS, 진단, 치료기술,

Conformational ensemble of the full-length SARS-CoV-2 nucleocapsid (N) protein based on molecular simulations and SAXS data

분자 시뮬레이션 및 SAXS 데이터를 기반으로 한 전장 SARS-CoV-2 뉴클레오캡시드(N) 단백질의 구조적 앙상블

Article

Published on 2022-09-012022-09-11
Journal: Biophysical chemistry
[Category] COVID19(2023년), SARS, 치료법,

Rational Design of CRISPR/Cas12a-RPA Based One-Pot COVID-19 Detection with Design of Experiments

실험 계획을 통한 CRISPR/Cas12a-RPA 기반 One-Pot COVID-19 탐지의 합리적 설계

Article

Published on 2022-04-152022-09-11
Journal: ACS synthetic biology
[Category] COVID19(2023년), SARS, 진단, 치료기술,

[키워드] accelerate addition amplification applied approach benefit buffer complex component components condition COVID-19 COVID-19 pandemic CRISPR CRISPR/Cas12a critical impact definitive screening design demonstrated design of experiments detection Detection sensitivity diagnostic Diagnostic method diagnostics DNA DNA sequence DoE Effect effective experiment Factor full-length SARS-CoV-2 Genome highlight isothermal molecular Molecular diagnosis N gene one-pot COVID-19 testing optimization polymerase reaction reaction optimization Reactions recombinase polymerase amplification recombinase polymerase amplification (RPA). reverse transcription RNA RNase RNase inhibitor robust RPA RT-qPCR sensitivity significant effect significantly simple statistical variables
[DOI] 10.1021/acssynbio.1c00617 PMC 바로가기 [Article Type] Article

MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters

MVA-CoV2-S 백신 후보는 우려의 구별되는 변종을 중화하고 햄스터의 SARS-CoV-2 감염으로부터 보호합니다

Article

Published on 2022-03-162022-09-11
Journal: Frontiers in Immunology
[Category] MERS, SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Against Alpha Beta candidate clinical trials concern control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 domain dose Efficacy elicited expressing favor full-length SARS-CoV-2 hamster hamsters IgG antibodies IgG antibody immunization immunogenicity Infectious virus lung Lung histopathology Lungs modified vaccinia virus MVA vaccine Neutralizing antibodies neutralizing antibody novel vaccines omicron pandemic parental Protein Receptor-binding domain reduction reduction in respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus significantly Spike. Vaccine vaccine candidate variants of concern Viral Viral RNA VOCs
[DOI] 10.3389/fimmu.2022.845969 PMC 바로가기 [Article Type] Article

Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2

SARS-CoV-2 S 단백질을 발현하는 폭스바이러스 MVA는 강력한 면역을 유도하고 SARS-CoV-2로부터 붉은털원숭이를 보호합니다

Article

Published on 2022-03-162022-09-11
Journal: Frontiers in Immunology
[Category] MERS, SARS, 변종, 진단,

[키워드] BAL Bronchoalveolar lavage caused Cell clinical trials Computed tomography COVID-19 COVID-19 pandemic cytokine Cytokine storm domain effective vaccine Effective vaccines Efficacy elicited expressing favor Fever full-length SARS-CoV-2 histological histological examination IFNγ IgG antibodies IgG antibody IL-4 immunogenic immunogenicity lung Lung pathology Lungs macaque macaques modified vaccinia virus MVA vaccine nasal mucosa Neutralizing antibodies neutralizing antibody novel Protein Receptor-binding domain reduced reduction rhesus rhesus macaque rhesus macaques robust Safe Safety SARS-CoV-2 SARS-CoV-2 S several variant several variants Spike. tomography vaccination Vaccine virus load
[DOI] 10.3389/fimmu.2022.845887 PMC 바로가기 [Article Type] Article

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication

Article

Published on 2022-01-182022-10-28
Journal: Viruses
[Category] COVID-19, SARS,

[키워드] A97V antiviral activity autonomous BAC Bacterial Cell culture chromosome clone coronavirus COVID-19 COVID-19 pandemic decrease drug Efficacy exhibited experiments F480L facilitated fluorescent full-length SARS-CoV-2 functional Genes genomic region genomic RNA GFP growth Healthcare system in vitro infectious virus inhibited membrane modify molecular clone Mutation nanoluciferase non-infectious Nsp12 P323L phenotype platform polymerase polymorphism Protein provide recombinant Remdesivir Replication replicon reporter Research resistance RNA virus SARS-CoV-2 SARS-CoV-2 mutants SARS-CoV-2 susceptibility SARS-CoV-2 variants sequence Substitution susceptibility System transcript Treatment utility Vaccines Vero E6 cell viral gene virus virus isolate
[DOI] 10.3390/v14020172 PMC 바로가기 [Article Type] Article

Production of full-length SARS-CoV-2 nucleocapsid protein from Escherichia coli optimized by native hydrophobic interaction chromatography hyphenated to multi-angle light scattering detection

다각도 광산란 검출에 하이픈으로 연결된 천연 소수성 상호작용 크로마토그래피에 의해 최적화된 대장균으로부터 전장 SARS-CoV-2 뉴클레오캡시드 단백질 생산

Article

Published on 2021-12-012022-09-11
Journal: Talanta
[Category] SARS, 치료기술, 치료법, 치료제,

[키워드] abundantly expressed acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis analytical method Cell cell lysis chaperone Chromatography complementary coronavirus cpCasp2‐based platform fusion protein process (CASPON technology). Critical diagnostic dimerized downstream Downstream processing (DSP) DSP E. coli enhanced enzyme-linked immunosorbent enzyme-linked immunosorbent assay Escherichia coli explained fermentation fraction full-length SARS-CoV-2 fusion protein host cell hydrophobic Hydrophobic interaction chromatography-multi-angle light scattering (HIC-MALS) Infection information Interaction life cycle mass spectrometry minor molecular MONITOR novel Novel coronavirus Novel coronavirus (termed SARS-CoV-2) Nuclease nucleic acids nucleocapsid protein nucleoprotein peptide platform produced Production Protein protein expression purification purified purity resolving power SARS-CoV-2 scattering SEC selectivity sequence severe acute respiratory syndrome Coronavirus target protein Treatment variable viral life cycle was used were expressed yield
[DOI] 10.1016/j.talanta.2021.122691 PMC 바로가기 [Article Type] Article

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

청소년 및 노인의 SARS-COV-2 재조합 스파이크 단백질 백신 (NVX-COV2373)의 상이한 용량 요법 : 2 상 무작위 위약 대조 시험

Clinical Trial

Published on 2021-10-012022-08-13
Journal: PLoS Medicine
[Category] Biochemistry, MERS, SARS, 임상, 진단,

[키워드] 95% CI 95% confidence interval accumulate addition Administered Adults adverse events age Anti-spike Antibody Response assessments assigned composed conducted convalescent sera coronavirus Day dose dose regimen Efficacy Endpoint Enrollment exceeded Follow-up Formica Frequency full-length SARS-CoV-2 geometric mean geometric mean titer geometric mean titers GMTs group groups identify IgG immune persistence immune response immune responses immunogenic immunogenicity Immunoglobulin Immunoglobulin G include inhibitory concentration intensity intramuscular dose lack limitation Matrix-M1 adjuvant median Mild mild to moderate moderate neutralizing antibody Neutralizing antibody response neutralizing antibody responses NVX-CoV2373 occurred less Older Older adults participant Participants Phase 1 Phase 2 Placebo placebo-controlled placebo-controlled trial primary endpoints Protein Randomized randomized placebo-controlled trial Randomly reactogenicity receive Recombinant spike protein regimen researcher respiratory Respiratory Coronavirus robust safety follow-up SARS-CoV-2 second dose second vaccination secondary endpoint seroconversion rate seroconversion rates severity short duration spike glycoprotein spike glycoproteins Spike protein Support The United States These data Tolerability Treatment Trial Trial registration trimeric United States USA vaccination Vaccine vaccine group wild-type virus
[DOI] 10.1371/journal.pmed.1003769 PMC 바로가기 [Article Type] Clinical Trial

Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters

Vaccinia 바이러스 기반 백신은 시리아 햄스터에서 SARS-COV-2 바이러스에 대한 보호 면역을 부여합니다.

Research Article

Published on 2021-09-092022-09-10
Journal: PLoS ONE
[Category] SARS, 변종, 진단,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus adenovirus-based Beta C57BL/6 candidate Candidates cause caused cold chain Coronavirus-2 Coronaviruses COVID-19 disease effective Express full-length SARS-CoV-2 full-length SARS-CoV-2 spike protein hamster hamsters Human immune response immune responses induce infected individual infected individuals Infection mammalian cells mice Mortality MOST mRNA Neutralizing antibodies neutralizing antibody Prevent protective immunity recombinant vaccine recombinant vaccines regimen regimens respiratory Respiratory illness SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine SARS-CoV-2 vaccines SARS-CoV-2 variant SARS-CoV-2 virus Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 severe respiratory illness Spike protein vaccination Vaccine vaccine platform vaccinia vaccinia virus variant Viral viral spread viral strain viral strains virus
[DOI] 10.1371/journal.pone.0257191 PMC 바로가기 [Article Type] Research Article

Dating the Common Ancestor from an NCBI Tree of 83688 High-Quality and Full-Length SARS-CoV-2 Genomes

83688 고품질 및 전장 SARS-COV-2 게놈의 NCBI 트리에서 공통 조상과 데이트

Article

Published on 2021-09-082022-09-10
Journal: Viruses
[Category] SARS, 유전자 메커니즘,